Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC (NCT04550260)
A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).
Who can join: Review the eligibility criteria below.
Location: Research Site — Atlanta, Georgia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (133 Sites)
Showing the first 25 of 133 sites.
- Research Site — Atlanta, Georgia
- Research Site — Louisville, Kentucky
- Research Site — Dallas, Texas
- Research Site — Fairfax, Virginia
- Research Site — Morgantown, West Virginia
- Research Site — Brussels,
- Research Site — Charleroi,
- Research Site — Liège,
- Research Site — Namur,
- Research Site — Barretos,
- Research Site — Fortaleza,
- Research Site — Porto Alegre,
- Research Site — Porto Alegre,
- Research Site — Rio de Janeiro,
- Research Site — São José do Rio Preto,
- Research Site — Vitória,
- Research Site — Barrie, Ontario
- Research Site — Greater Sudbury, Ontario
- Research Site — Anyang,
- Research Site — Beijing,
- Research Site — Beijing,
- Research Site — Bengbu,
- Research Site — Changsha,
- Research Site — Changzhi,
- Research Site — Chengdu,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Esophageal Squamous Cell Carcinoma
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy — Fort Myers, Florida
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) — Pittsburgh, Pennsylvania
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) — Tucson, Arizona
- Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer — Montreal, Quebec
- A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types — Denver, Colorado
Explore by condition: All Esophageal Squamous Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.